Profile and outcome of cancer patients enrolled in contemporary phase I trials

Emily Alouani,Anas Gazzah,Sandrine Mercier,Ratislav Bahleda,Antoine Hollebecque,Jean-Marie Michot,Capucine Baldini,Samy Ammari,Stephane Champiat,Aurelien Marabelle,Sophie Postel-Vinay,Vincent Ribrag,Yohann Loriot,Santiago Ponce Aix,Linda Mahjoubi

European Journal of Cancer（2023）

引用 0|浏览36

暂无评分

摘要

•Overall, 15.9% objective response rate and 45.4% disease control rate in phase I trials.•mPFS and mOS, respectively, of 2.6 months and 12.4 months.•Phase I trials represent a valid option for patients in oncology.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要